
Ambassador Ma. Theresa Dizon-de Vega announces the Government of the Republic of the Philippines has made a donation to the International Vaccine Institute. She poses for a photo with IVI’s Director General Dr. Jerome Kim. Photo: IVI
March 14, 2023 – SEOUL, Republic of Korea – The Philippine Ambassador to the Republic of Korea, H.E. Ma. Theresa Dizon-de Vega, announced that the Government of the Republic of the Philippines has made a voluntary contribution to the International Vaccine Institute, an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
Dr. Jerome Kim, Director General of IVI, said: “We are grateful to the Government of the Republic of the Philippines for its continued trust in and support of IVI and our work to research and develop vaccines against infectious diseases that affect the world’s most vulnerable populations. As a founding signatory and State Party of IVI since 2004, the Philippines has been a valuable collaborator in vaccine clinical development projects and disease burden studies to protect and save millions of lives at risk of poverty-associated diseases such as typhoid fever, dengue, cholera, and tuberculosis.”
“With this modest funding commitment, the Philippines looks forward to supporting IVI’s recent efforts in infectious disease research and vaccine research and development, helping create a platform for dialogue and future collaboration, and continuing our close relationship with the IVI as a State Party and supporter in the years to come,” Ambassador Dizon-de Vega said.
Ambassador Dizon-de Vega announced the $20,000 USD contribution during her welcoming remarks for IVI’s Vaccine Diplomacy Day, an event commemorating First Lady Kim Keon Hee’s inauguration as the 5th Honorary President of the Korea Support Committee for IVI, a role traditionally held by incumbent First Ladies of the Republic of Korea.
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.
CONTACT
Aerie Em, Global Communications & Media Specialist
+82 2 881 1386 | aerie.em@ivi.int